<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611881</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000539/PHS</org_study_id>
    <nct_id>NCT03611881</nct_id>
  </id_info>
  <brief_title>Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)</brief_title>
  <acronym>ScreenASSIST</acronym>
  <official_title>Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial seeks to evaluate the effectiveness of alternative&#xD;
      strategies to integrate smoking cessation interventions into the delivery of low-dose CT&#xD;
      (LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be&#xD;
      randomly assigned to receive these interventions: (1) smoking cessation counseling support by&#xD;
      telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch&#xD;
      treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no&#xD;
      referral) to an online resource to connect smokers to a community-based social service&#xD;
      resources.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence-based tobacco dependence treatment consists of behavioral counseling and&#xD;
      pharmacotherapy. Nicotine patch is an FDA-approved cessation aid. The optimal duration of&#xD;
      counseling and pharmacotherapy for patients undergoing low-dose CT (LDCT) lung screening is&#xD;
      not clear. In addition, helping smokers to address other social and psychological barriers&#xD;
      might help them succeed in quitting smoking. This randomized controlled trial will test, in a&#xD;
      factorial design, two options for delivering each of 3 interventions to help current smokers&#xD;
      stop smoking in the context of having routine CT lung cancer screening. Patients will receive&#xD;
      4 or 8 weeks of behavioral counseling (with their choice of video conferencing or regular&#xD;
      telephone calls), 2 or 8 weeks of nicotine patch, and will receive referral (vs. no referral)&#xD;
      to an online resource to connect smokers to community-based social service resources. Outcome&#xD;
      measures for smoking cessation will be assessed by a survey administered by phone at 3,and 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported past 7-day smoking abstinence</measure>
    <time_frame>6 Months after enrollment</time_frame>
    <description>Patient self-report of no cigarette smoking in the past 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported past 7-day smoking abstinence</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Patient self-report of no cigarettes smoked in the past 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &gt;50% reduction in cigarettes smoked per day</measure>
    <time_frame>3 Months</time_frame>
    <description>&gt;50% decrease in cigarettes smoked per day between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &gt;50% reduction in cigarettes smoked per day</measure>
    <time_frame>6 months</time_frame>
    <description>&gt;50% decrease in cigarettes smoked per day between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who make an intentional attempt to quit smoking</measure>
    <time_frame>3 months</time_frame>
    <description>Intentional attempt to quit smoking cigarettes that lasts for &gt;=24 hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biochemically-verified past 7-day abstinence from cigarette smoking</measure>
    <time_frame>6 Months - no longer in use after 7/6/2020</time_frame>
    <description>Patient report of no cigarettes smoked in the past 7 days (point prevalence abstinence), confirmed biochemically by saliva cotinine &lt;=10 ng/ml or expired air carbon monoxide (CO) &lt;10 ppm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemically-verified past 7-day abstinence from cigarette smoking</measure>
    <time_frame>3 Months - no longer in use after 7/6/2020</time_frame>
    <description>Patient report of no cigarettes smoked in the past 7 days (point prevalence abstinence), confirmed biochemically by saliva cotinine &lt;=10 ng/ml or expired air carbon monoxide (CO) &lt;10 ppm.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Smoking, Tobacco</condition>
  <arm_group>
    <arm_group_label>Short, Short, Present</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short, Long, Present</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long, Short, Present</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long, Long, Present</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short, Short, Absent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short, Long, Absent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long, Short, Absent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long, Long, Absent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>4 or 8 weeks of behavioral counseling support to promote smoking cessation.</description>
    <arm_group_label>Long, Long, Absent</arm_group_label>
    <arm_group_label>Long, Long, Present</arm_group_label>
    <arm_group_label>Long, Short, Absent</arm_group_label>
    <arm_group_label>Long, Short, Present</arm_group_label>
    <arm_group_label>Short, Long, Absent</arm_group_label>
    <arm_group_label>Short, Long, Present</arm_group_label>
    <arm_group_label>Short, Short, Absent</arm_group_label>
    <arm_group_label>Short, Short, Present</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.</description>
    <arm_group_label>Long, Long, Absent</arm_group_label>
    <arm_group_label>Long, Long, Present</arm_group_label>
    <arm_group_label>Long, Short, Absent</arm_group_label>
    <arm_group_label>Long, Short, Present</arm_group_label>
    <arm_group_label>Short, Long, Absent</arm_group_label>
    <arm_group_label>Short, Long, Present</arm_group_label>
    <arm_group_label>Short, Short, Absent</arm_group_label>
    <arm_group_label>Short, Short, Present</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Community Resource</intervention_name>
    <description>Counselor-facilitated referral to a community-based program to address social needs.</description>
    <arm_group_label>Long, Long, Present</arm_group_label>
    <arm_group_label>Long, Short, Present</arm_group_label>
    <arm_group_label>Short, Long, Present</arm_group_label>
    <arm_group_label>Short, Short, Present</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo LDCT-LCS at a participating Mass General Brigham Health Care&#xD;
             System LCS site&#xD;
&#xD;
          -  Speak English or Spanish.&#xD;
&#xD;
          -  Current smokers: smoked a cigarette, even a puff, in the last 30 days.&#xD;
&#xD;
          -  Medicare coverage requirement (age 50-80 years, 20+ pack/years).&#xD;
&#xD;
          -  Residing within the USA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergoing lung CT as part of a diagnostic or abnormal follow-up evaluation.&#xD;
&#xD;
          -  Unable to give informed consent due to psychiatric or cognitive impairment as&#xD;
             determined in consultation with study PI or treating clinician.&#xD;
&#xD;
          -  No access to a telephone or cannot communicate by telephone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elyse R Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy A Rigotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Haas, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elyse R Park, Ph.D.</last_name>
    <phone>(617) 724-6836</phone>
    <email>epark@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caylin J Marotta, MPH</last_name>
    <phone>(617) 724-1861</phone>
    <email>screenassist@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse R Park, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Haas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Prabhakar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martha's Vineyard Hospital</name>
      <address>
        <city>Oak Bluffs</city>
        <state>Massachusetts</state>
        <zip>02557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Pil, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elyse Park, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>lung screening</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

